WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Open this folder and view contentsEczematous diseases
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Open this folder and view contentsBullous dermatoses
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Open this folder and view contentsAntimicrobial drugs
Open this folder and view contentsAntifugal drugs
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Close this folderScabicides and pediculicides
View the documentBenzyl benzoate
View the documentLindane
View the documentPermethrin
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Open this folder and view contentsUltraviolet radiation-blocking agents (sunscreens)
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover
 

Permethrin

Cream, 5%

General information

Permethrin is a topical scabicidal agent for the treatment of infestations with Sarcoptes scabiei, Pediculus humanus capitis and P. humanus corporis. It acts on the nerve cell membranes of the parasites with consequent paralysis. It is more expensive than lindane and benzyl benzoate.

Absorption of permethrin is negligible following topical application.

Clinical information

Uses

Treatment of scabies and pediculosis of the scalp and body.

Dosage and administration

All doses are suitable for adults and children.

Scabies and Pediculus humanus corporis:

The cream should be massaged thoroughly into all skin surfaces, from the scalp to the soles of the feet, and left for at least 8 hours before rinsing. In general, 30 g is sufficient for an average adult. A single application is usually curative.

Pediculus humanus capitis:

The cream should be massaged into damp hair and left for 10 minutes before rinsing.

Household contacts should be treated at the same time. All combs and brushes should be soaked in a pediculicidal solution (see Parasitic infections - Prevention and management) for at least 2 hours.

Contraindication

Known hypersensitivity to synthetic pyrethroids or pyrethrins.

Use in pregnancy

Safe use in pregnancy has not been demonstrated. However, since absorption is negligible, it may be used if necessary.

Precautions

Pruritus, oedema and erythema may be exacerbated.

Adverse effects

Mild and transient burning and stinging sensations may occur after treatment, particularly in cases with severe infestation.

Storage

Cream should be stored in well-closed containers, below 25 °C.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019